DHSC gives go ahead for boys to receive HPV vaccine

DHSC gives go ahead for boys to receive HPV vaccine

July 27 2018 Adolescent boys will be offered the human papilloma virus (HPV) vaccine to protect...

Home Office gives go ahead to allow cannabis-derived products on prescription

Home Office gives go ahead to allow cannabis-derived products on prescription

July 27 2018 Certain cannabis-derived products will be reclassified as Class 2 medicinal...

New law strengthens punishment for assaulting health sector workers

New law strengthens punishment for assaulting health sector workers

July 27 2018 A new law will increase the possible sentencing of someone who commits common...

Asthma deaths levels increase by a quarter in a decade

Asthma deaths levels increase by a quarter in a decade

July 26 2018 There were 1,320 deaths due to asthma in England and Wales in 2017, the highest...

Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

July 24 2018 New Health Secretary Matt Hancock has called for investment in primary care and...

  • DHSC gives go ahead for boys to receive HPV vaccine

    DHSC gives go ahead for boys to receive HPV vaccine

    Friday, 27 July 2018 16:22
  • Home Office gives go ahead to allow cannabis-derived products on prescription

    Home Office gives go ahead to allow cannabis-derived products on prescription

    Friday, 27 July 2018 16:19
  • New law strengthens punishment for assaulting health sector workers

    New law strengthens punishment for assaulting health sector workers

    Friday, 27 July 2018 16:16
  • Asthma deaths levels increase by a quarter in a decade

    Asthma deaths levels increase by a quarter in a decade

    Thursday, 26 July 2018 15:29
  • Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

    Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

    Tuesday, 24 July 2018 13:07

ApprovalJune 22 2016

The All Wales Medicines Strategy Group has announced two new recommendations for medicines by the NHS in Wales. The Scottish Medicines Consortium has recommended four medicines for use, but has also advised against two others.

The AWSMG recommendations are:

• dulaglutide (Trulicity) for restricted use in type 2 diabetes in adults to improve glycaemic control where standard triple therapy (metformin and two other antidiabetic medicines) is ineffective or inappropriate as an alternative to insulin therapy. It can also be used in combination with other glucose-lowering medicinal products but not insulin, when these, together with diet and exercise, have not provided adequate glycaemic control.
• pasireotide (Signifor) for treating adults with acromegaly when surgery is not an option or has not been curative and other somatostatin analogues are not adequately controlling the condition;
In Scotland, the SMC approvals are for:
• co-careldopa (Duodopa) for advanced Parkinson’s disease, administered as a gel directly into the small intestine via a pump and tubing surgically inserted into the gut;
• mepolizumab (Nucala) for severe eosinophilic asthma;
• blinatumomab (Blincyto) for acute lymphoblastic leukaemia;
• febuxostat (Adenuric) for patients at risk of Tumour Lysis Syndrome (TLS), a complication due to the breakdown of cancer cells leading to a rise in uric acid level in the blood which can then cause kidney damage.

The Committee was unable to accept cabazitaxel (Jevtana) for advanced prostate cancer and evolocumab (Repatha) for high cholesterol.

Asthma UK has welcomed the SMC decision on mepolizumab, but has expressed concern that NICE is proposing not to recommend the drug for use in England. Dr Samantha Walker, Asthma UK's Director of Research and Policy, said:

“Whilst Asthma UK has worked very hard to make sure that use of this crucial treatment for people with severe asthma was accepted in Scotland, which we are delighted to see, we have grave concerns over the difference in the situation in England.

“Mepolizumab has been shown to be clinically effective at reducing severe asthma symptoms in people with a certain type of asthma and should be available to those people who are most likely to benefit from it. Obviously this needs to be at a price that the NHS can afford, so it is essential that NICE and the manufacturer continue to work together and find a solution.”

Links:

AWSMG decisions

SMC announcement

Asthma UK comment

Professional News

July 27 2018 Adolescent boys will be offered the human papilloma virus (HPV) vaccine to protect them from cancer, the Department of Health and Social Care has announced.
July 20 2018 Doctors are being reminded to ensure that any patient or other records which may be relevant to the UK Infected Blood Inquiry are not destroyed. Earlier this month, the Inquiry’s Chair, Sir...